This study analyzed the prognosis of ICI treatment and NCOR1 mutations in patients with bladder cancer and attempted to elucidate the underlying mechanism of NCOR1-MT as a biomarker for screening the predominant population of bladder cancer preferred for immunotherapy; however, there are still some limitations. The gene discussed is NCOR1; the disease is urinary bladder cancer.